2.40
+0.02(+0.84%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
16
First IPO Date
June 21, 2010
| Name | Title | Pay | Year Born |
| Dr. Pardeep Nijhawan FRCPC, M.D. | Chief Executive Officer, Company Secretary & Director | 464,728 | 1971 |
| Dr. Michael J. Brooks M.B.A., Ph.D. | President | 428,987 | 1979 |
| Mr. Peter John Weiler M.B.A, M.Sc. | Chief Financial Officer | 0 | 1969 |
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.